Skip to main content
Download PDF

Endothelial nitric oxide synthase Asp298Glu (894G/T) gene polymorphism as a possible risk factor for the coronary slow flow phenomenon among Iranians

BMC Cardiovascular Disorders volume 22, Article number: 300 (2022) Cite this article

Abstract

Background

Mounting evidence indicates an association between endothelial dysfunction and the coronary slow flow phenomenon (CSFP). In the present study, we aimed to evaluate the possible role of endothelial nitric oxide synthase (eNOS) 894G/T and interleukin-1β (IL-1β) 315C/T polymorphisms as possible risk factors for CSFP.

Methods

This prospective study enrolled patients with CSFP and individuals with normal coronary arteries. Genotypes were assessed using regular polymerase chain reaction and direct Sanger-sequencing techniques.

Results

The study population consisted of 267 individuals: 180 patients with CSFP (49 women [27.2%]) at a median age of 55 (48–62) years and 87 controls with normal coronary arteries (56 women [64.4%]) at a median age of 47 (41–58) years. The allelic distribution of eNOS 894G/T was significantly associated with CSFP (odds ratio [OR], 1.58; 95% confidence interval (CI), 1.04–2.42; P = 0.03). This polymorphism increased the risk of CSFP under the dominant model (OR 1.73; 95% CI I.02–2.95; P = 0.04). However, the allelic frequencies (1.05; 95% CI 0.68–1.59; P = 0.83) and genotypic frequencies (0.88; 95% CI 0.52–1.49; P = 0.63) of the IL-1β 315C/T polymorphism were not associated with the incidence of CSFP in the Iranian population.

Conclusions

The CSFP and control groups were statistically different regarding the eNOS 894G/T polymorphism. Our findings also demonstrated that the IL-1β 315C/T polymorphism was not a risk factor for CSFP.

Peer Review reports

Introduction

The coronary slow flow phenomenon (CSFP), an uncommon disease, is an angiographic finding characterized by the delayed opacification of the distal branch of the coronary arteries in the absence of obstructive coronary artery disease [1, 2]. It is only found in 7% of patients with coronary artery disease undergoing diagnostic angiography [3]. CSFP seems to be multifactorial, and its precise etiopathological mechanisms have yet to be elucidated [4]. Morphological abnormalities such as fibromuscular hyperplasia, medial hypertrophy, myointimal proliferation, and subclinical atherosclerosis, as well as anatomic factors, functional abnormalities, and inflammation, have been proposed as the pathogenic factors of the disease [1, 4, 5]. Mounting evidence indicates common single-nucleotide polymorphisms (SNPs) residing in different genes as genetic risk factors for CSFP [6,7,8,9].

Nitric oxide (NO) is a vasodilator synthesized from L-arginine by endothelial nitric oxide synthase (eNOS), which is encoded by a single eNOS (NOS3) gene located on chromosome 7q35-q36 [10]. One of the most studied SNPs of eNOS is 894G/T (rs1799983), which results in the decreased production of NO and is significantly associated with coronary artery disease in different populations [11,12,13,14,15,16,17]. In addition, numerous studies have indicated that the plasma level of NO is significantly lower in patients with CSFP than in healthy controls [9, 18,19,20]. The interleukin-1 (IL-1) family comprises a group of proinflammatory cytokines composed of α and β types. The family, the product of the IL-1 gene, modulates the chronic inflammatory response by increasing leukocyte adhesion to damaged endothelia, although several mediators are involved in the atherosclerosis process and cardiovascular disease [21].

The literature contains conflicting reports on the relationship between CSFP and eNOS 894G/T (rs1799983, Asp298Glu) and IL-1β 315C/T (rs1143634, Phe105 =) from studies carried out on different populations across the world [7, 9, 22,23,24,25].

In the present study, we sought to investigate the association between CSFP and eNOS 894G/T (rs1799983, Asp298Glu) and IL-1β 315C/T (rs1143634, Phe105 =) in a sample of the Iranian population, divided into patients with CSFP and normal individuals.

Methods

Study population

The study population was selected from candidates for coronary angiography in Rajaie Cardiovascular Medical and Research Center in Tehran, Iran. Patients with valvular heart disease, congenital heart disease, arrhythmia, connective tissue disease, collagen vascular disease, and more than 25% obstruction in the vessel diameter were excluded. The control group was chosen from individuals in whom diagnostic coronary angiography showed no coronary artery disease. Peripheral blood samples were taken from all the participants to determine genotypes, lipid profiles, cardiac enzyme levels, creatinine levels, cell blood counts, and erythrocyte sedimentation rates. The blood samples for genetic analysis were preserved at – 70 °C.

The study protocol was approved by the Ethics Committee of Rajaie Cardiovascular Medical and Research Center (IR.RHC.REC.1399.075), and the study was conducted in accordance with the Helsinki Declaration.

Definition of CSFP

CSFP was diagnosed via the thrombolysis in myocardial infarction frame count (TFC) method.1 Participants with a corrected TFC greater than 2 standard deviations from the published normal range for the particular vessel were considered to have CSFP (the left anterior descending coronary artery (LADA) > 36.2 ± 2.6, the left circumflex artery (LCx) > 22.2 ± 4.1, and the right coronary artery (RCA) > 20.4 ± 3.0).

The standard method was drawn upon for left heart catheterization and coronary angiography. CSFP was defined based on the TFC method introduced by Gibson [26]. The number of cine frames required for the contrast to reach the standard landmark in the distal coronary artery is termed “TFC.” The first frame in TFC is obtained when the contrast material enters the coronary artery completely, with the entrance having 3 characteristics: (1) The contrast material should fill the full thickness of the vessel. (2) The contrast material should be in contact with both margins of the vessel. (3) The contrast agent should move forward. The last frame is obtained when the contrast material enters the distal landmark branch. The distal landmark branches are defined for each vessel separately: the last 2 branches for the left anterior descending, the last obtuse marginal branch for the left circumflex artery, and the first branch of the posterior left ventricular branch for the right coronary artery. The images were obtained at a rate of 15 frames per second, and the results were multiplied by 2. The frame counts of the left anterior descending were divided by 1.7 for correction because of its length. Patients who had a frame count above 27 for all vessels were considered to have CSFP.

Genotyping of the eNOS and IL-1β gene polymorphisms

DNA extraction

Genomic DNA was extracted from the peripheral blood samples, collected in EDTA tubes, using the salting-out method and the Exgene Blood SV Mini Kit (GeneAll, Seoul, South Korea). The NanoDrop Spectrophotometer (Thermo Fisher Scientific, US) was employed to determine the quantity of the extracted DNA.

Polymerase chain reaction (PCR) and direct Sanger sequencing

Appropriate PCR oligonucleotides were designed to amplify the desired part of the IL-1β and eNOS3 genes by utilizing the Gene Runner (Gene Runner 6.5.50) and PerlPrimer (PerlPrimer 1.1.21) software tools. Further, 5′-AAGGCAGGAGACAGTGGATG-3′ (forward), 5′-CAATTTCCAGCAGCATGTTG-3′ (reverse), 5′-CGTATATGCTCAGGTGTCCTC-3′ (forward), and 5′-CATGGAGAATTAGCAAGCTG-3′ (reverse) primers were used to amplify the part of eNOS (385 base pairs in length) and IL-1β (230 base pairs in length) that covered the desired variations with the following thermal program: 94 °C for 35 s, 63 °C (eNOS) or 55 °C (the IL-1β variant) for 30 s, and 72 °C for 45 s, with a final extension at 72 °C for 10 min. Amplicons were electrophoresed on a 1.5% agarose gel, stained with ethidium bromide, and visualized under ultraviolet light.

All the PCR products were subjected to direct Sanger sequencing with the ABI 3500 DNA Sequencer (Applied Biosystems, CA, US). The reverse primer of eNOS3 and the forward primer of IL-1β were used for direct sequencing.

Statistical analysis

HGMD [27], NCBI [28], UCSC [29], and VarSome [30] databases were utilized to evaluate the selected SNPs and the pathogenesis of the selected mutations.

The BioEdit software (BioEdit 7.2.1) was run to analyze the sequencing outcomes. The results were analyzed using the IBM SPSS statistics 26, the GraphPad Prism 9 software, and the SNPSTAT analyzer [31].

The 1-sample Kolmogorov–Smirnov test was first applied to test the normality of the data. Qualitative data were presented as numbers and percentages. The association between categorical variables was assessed using the χ2 test; and if 20% of the cells had the expected count of lower than 5, the Fisher exact test was employed. Quantitative data were described as the medians (Q1–Q3) for nonparametric data. The independent samples t test was applied to compare the mean values, and the Mann–Whitney test was used to compare the median values between 2 groups. Additionally, ANOVA and Kruskal–Wallis tests were drawn upon to compare the mean and median values between more than 2 groups. Finally, the multivariable regression analysis was applied using STATA 13.

Results

Clinical characteristics of the study population

From 2016 through 2017, a total of 180 patients with CSFP (49 women [27.2%]) at a median age of 55 (48–62) years were enrolled in the CSFP group. From 2016 through 2018, a total of 87 individuals with normal coronary arteries (56 women [64.4%]) at a median age of 47 (41–58) years were enrolled in the control group. The baseline and clinical characteristics of both groups are summarized in Table 1. Table 2 shows the clinical and laboratory characteristics of the CSFP group. Both groups were similar regarding baseline characteristics and laboratory data except for age and sex. The patient and control groups were similar in terms of dyslipidemia, diabetes mellitus, hypertension, smoking, and a family history for coronary artery disease. Additionally, the levels of plasma creatinine, triglyceride, and hemoglobin were higher in the patients with CSFP than in the control group. The median value (Q1–Q3) TFC for the left anterior descending coronary artery, the left circumflex artery, and the right coronary artery was 36 (29–43), 40 (31–50), and 31.5 (24–40), respectively, in the CSF group.

Table 1 Comparison of baseline characteristics and lab data between the CSFP and control groupsa,b
Full size table
Table 2 Clinical, laboratory, and angiographic characteristics of the CSFP groupa,b
Full size table

Allelic and Genotype Distributions of eNOS 894G/T and IL-1β 315C/T

The results concerning the allelic and genotype distributions of the eNOS3 and IL-1β polymorphisms are depicted in Table 3. The genotype frequencies of eNOS 894G/T polymorphism was in accordance with the Hardy–Weinberg equilibrium in the CSFP group (χ2 = 1.484, P = 0.48) and in control group (χ2 = 0.1867, P = 0.91). Likewise, the genotype frequencies of IL-1β 315C/T polymorphism was in line with those predicted by the Hardy–Weinberg equilibrium in the CSFP group (χ2 = 0.3557, P = 0.84) and in control group (χ2 = 6.446, P = 0.04).

Table 3 Distributions of the eNOS3 864G/T and IL-1β 315C/T alleles and genotypes in the CSFP and control groups
Full size table

In the univariate analysis of eNOS 894G/T, the frequencies of the T allele in the patient and control groups were 20% and 29%, respectively, and a significant difference was found in the allelic distribution of eNOS (odds ratio [OR], 1.58; 95% confidence interval [CI], 1.04–2.42; P = 0.03). Consequently, the higher presence of the T allele of eNOS in the control group hinted at a protective effect exerted by this allele on the study population. In the CSFP and control groups, respectively, the frequency of the G/G genotype was 65% versus 51.7%, the frequency of the G/T genotype was 29.4% versus 39.1%, and the frequency of the T/T genotype was 5.6% versus 9.2%. The analysis of the genotype distribution in the 2 groups demonstrated a significant association between the presence of the T allele of eNOS and CSFP (OR 1.73; 95% CI 1.02–2.95; P = 0.04) in a dominant model. Nonetheless, no significant differences were found between the recessive model and the codominant model.

In the univariate analysis of IL-1β 315C/T, the frequency of the T allele was estimated to be 24% and 25% in the patients and controls, respectively, and no significant difference was found in the allelic distribution of IL-1β (P = 0.83). The frequencies of the C/C, C/T, and T/T genotypes were 57.9% versus 60.9%, 35.4% versus 27.6%, and 6.7% versus 11.5% in the patients with CSFP and the participants with normal coronary arteries, respectively (P = 0.25). Additionally, no significant differences in genotype distribution were found in the dominant (P = 0.63), recessive (P = 0.19), and codominant (P = 0.25) models between the patients and the healthy controls concerning IL-1β.

Furthermore, the association between the CSFP phenotype and the combined genotypes of the eNOS and IL-1β polymorphisms was assessed, and the results were nonsignificant (P = 0.12) (data not shown).

In the multivariable regression analysis, age (OR 1.08; 95% CI; 1.03 to 1.12; P < 0.01) and the male sex (OR 0.22; 95% CI 0.08 to 0.62; P < 0.01) were the only independent predictors of CSFP in the study population. In addition, no significant associations were found between the presence of the mutant allele and the wild type for the eNOS and IL-1β polymorphisms with the application of the multivariable analysis (OR 0.46; 95% CI 0.11 to 1.98; P = 0.29 for eNOS, and OR 0.47; 95% CI 0.13 to 1.7; P = 0.24 for IL-1β) (Table 4).

Table 4 Multivariable logistic regression analyses of the possible predictors of CSFP in the study population
Full size table

Relationships Between the eNOS3 864G/T and IL-1β 315C/T Genotypes and TFC and Electrocardiographic Findings in the CSFP Group

According to the univariate analysis, the median values of TFC for the left anterior descending (P = 0.80), the left circumflex (P = 0.16), and the right coronary artery (P = 0.80) were not significantly different between the individuals with different genotypes of eNOS 894G/T. Moreover, no significant differences were found in terms of the median values of TFC for the left anterior descending (P = 0.53) and the left circumflex (P = 0.11) between the genotypes of IL-1β 315C/T. However, the median value of TFC for the right coronary artery was different between the IL-1β genotypes (P < 0.01; Table 5).

Table 5 Relationships between the eNOS3 864G/T and IL-1β 315C/T genotypes and TFC findings of the CSFP groupa
Full size table

Sex (coefficient, − 3.48; 95% CI − 7.06 to 0.11; P = 0.05) was the only predictor of TFC for the left anterior descending, and no statistically significant associations were found between TFC for the left anterior descending and the presence of the T allele of the eNOS 864 T/G polymorphism, the presence of the mutant allele of the IL-1β 315C/T polymorphism, body mass index, systolic blood pressure, and left ventricular ejection fraction in the multivariable regression analysis (P > 0.05) (Additional file 1: Table S1).

Further, all 180 patients with CSFP underwent electrocardiography. Among them, ST-T changes were positive in 43 patients (23.9%), of whom 17 (39.5%) had the T allele in the eNOS3 locus. No significant differences were noted in electrocardiographic findings between the eNOS3 genotypes.

Similar to the eNOS results, no significant associations were found in electrocardiographic findings between the different genotypes of the studied IL-1β SNP. The distribution of the IL-1β genotypes was similar among those with a positive ST-T change finding (P = 0.26).

Discussion

In the present study, we examined the association between CSFP and eNOS3 (894G/T) and IL-1β (315C/T) polymorphisms in a sample of the Iranian population. Our results indicated that the distribution of the Asp298Glu variant of the eNOS gene was significantly different between patients with CSFP and controls with normal coronary arteries. Further, the mutant allele T of eNOS 894G/T polymorphism was lower in the CSFP suggesting that this polymorphism is protective. While there was no significant association between the IL-1β gene (315C/T) variant and CSFP in our studied population. We also assessed associations in diagnostic tests, clinical information, and lab data between the eNOS3 (894G/T) and IL-1β (315C/T) variants and found no significant associations.

CSFP was first defined by Tambe et al. in 1972 as a delay in the progression of the contrast dye injected into the coronary arteries during coronary angiography without any obstructive disease [32]. The phenomenon is diagnosed mainly with an increased TFC. Although the etiology and pathogenesis of CSFP are not well-known, impaired balances between vasoconstrictor and vasodilator factors and increased inflammatory markers have been suggested [4, 9, 33]. Urotensin-II, as a potent vasoconstrictor, has been reported as a possible risk factor for CSFP (OR 1.01; 95% CI 1.00–1014; P = 0.01) [34]. Furthermore, aortic pulse pressure and the pulsatility index in patients with CSFP tend to rise remarkably due to endothelial dysfunction. The role of inflammation in the pathophysiology of CSFP was expounded by Aksn G et al., who found that the serum levels of neutrophil gelatinase-associated lipocalin, as an inflammatory biomarker, were significantly higher in patients with CSF than in those with a normal coronary flow [35]. In addition, the hematocrit level, as well as erythrocyte, eosinophil, and basophil counts, was increased in patients with CSF compared with the group with a normal coronary flow, which may support the previous hypothesis [36]. Substantial evidence suggests that the eNOS Glu298Asp polymorphism is responsible for endothelial dysfunction [37,38,39].

NO plays a significant role as a vasorelaxation factor and has a protective effect on atherogenesis [40]. It has been shown that several polymorphisms of eNOS (NOS3) affect the serum level of NO [41]. Notably, the eNOS Asp298Glu polymorphism may be associated with CSFP in that it decreases the serum levels of NO. Moreover, the IL-1β gene, which releases IL-1β as a proinflammatory agent, is associated with cardiovascular diseases, including coronary artery disease, stent restenosis after percutaneous coronary interventions, carotid artery disease, lone atrial fibrillation, and CSFP [42,43,44,45]. In addition, the 315C/T nucleotide transition of the IL-1β gene probably modulates IL-1β protein synthesis and is associated with such cardiovascular diseases as CSFP, coronary artery disease, and myocardial infarction [25, 46,47,48,49].

Previous studies have also indicated the role of genetic predisposing factors in the occurrence of CSFP [22,23,24, 50].

There are dissimilarities in the frequencies of eNOS3 894G/T alleles in different races. Such differences have given rise to controversy as regards the application of the G allele as a mutant. The VarSome database recognizes the T allele as the reference allele, and the Iranome database also cites the same allele for the Iranian population. [51, 52]. However, the T allele has been reported as a possible risk factor for stroke and periventricular white matter hyperintensities [53, 54]. Marwa Ben et al. concluded that eNOS3 894G/T was significantly associated with coronary artery disease in additive and dominant models (but not in recessive models), concordant with our findings [55]. In Pakistan, Nawaz et al. reported that the frequency of the T allele was higher than that of the G allele and introduced the TT genotype as a strong risk factor for coronary artery disease [56]

Controversy, however, abounds regarding the association between CSFP and eNOS3 894G/T SNPs in different populations. In samples of the Turkish population, Caglayan et al. and subsequently Sezgin et al. reported no associations between 894G/T SNP and CSFP [9, 57]. Caglayan and colleagues assessed 85 individuals, consisting of 66 patients with CSFP and 19 subjects with normal coronary arteries, while they excluded patients with diabetes mellitus; hypertension; coronary artery disease history; coronary ectasia; atrial fibrillation; complete bundle branch block; serious conduction defects; mitral valve prolapse; hypertrophic, restrictive, and dilated cardiomyopathies; left ventricular hypertrophy; ejection fractions less than 50%; and pulmonary, renal, hepatic, and hematological disorders. In this study, the frequency of the variant allele was 0.41 and 0.38 in the control and patient groups, respectively. No statistically significant differences were found in allelic and genotype distributions between the CSFP and control groups. Sezgin and colleagues recruited 30 patients with CSFP and no other cardiac disease and 61 control subjects and reported no association between eNOS intron 4 VNTR and 894G/T polymorphisms. Nevertheless, the plasma levels of NO were significantly lower in the CSFP group than in the control group (P < 0.05). In contrast, Gupta et al. reported a strong association between this nucleotide transition and CSFP in the North Indian population and suggested the T allele as an independent risk factor for CSFP [24]. This study assessed 27 patients with CSFP and 200 individuals as the control group. The exclusion criteria were the same as those in the study by Caglayan and colleagues. The results showed a significant association between the presence of the T allele and CSFP (P = 0.014; w2 = 6.1). Our findings are different from those reported by the investigations in Turkey, but they chime in with those reported by Gupta and colleagues.

Mutluer et al. revealed an association between the rs1143634 of the IL-1β gene and CSFP in the Turkish population [48]. A study on the Han Chinese population reported an association between the IL-10 polymorphism and CSFP [45]. In contrast to the investigation in the Turkish population, our results showed no association between the 315C/T (rs1143634) of the IL-1β gene polymorphism and CSFP. It is worthy of note that had we recruited a larger population, our analysis might have yielded different results. To the best of our knowledge, this is the first report on the association between eNOS 894G/T and CSFP in the Iranian population. A previous investigation in Iran examined the predictive power of 2 common polymorphisms of the eNOS gene in relation to CSFP after primary percutaneous coronary interventions and reported no associations between CSFP and the 894G/T and − 786T/C polymorphisms of the eNOS gene [58]. Heidari et al. found an association between the − 813C/T (rs2070744) and 894G/T (rs1799983) polymorphisms of the eNOS gene and multiple sclerosis in Iranian patients [59]. In another study, no association was found between the 894G/T eNOS polymorphism and coronary artery disease in the northern Iranian population [60]. Accumulating evidence indicates that the Asp298Glu SNP of the eNOS gene is associated with coronary artery disease, ST-segment-elevation myocardial infarction, hypertension, coronary vasospasm, impaired coronary collateral development, impaired coronary blood flow, and obesity [14, 61,62,63,64,65,66,67].

Limitations

The observational nature of our investigation and its limited sample size precluded us from drawing a firm conclusion. Indeed, our results should be tested in a larger population to confirm the association between the studied eNOS gene polymorphisms and the IL-1β nucleotide transition. Additionally, the associations between the Asp298Glu transition of the eNOS gene and the plasma nitric oxide level and nitric oxide synthase activity were not assessed in this study due to technical and financial limitations. Finally, our results might have been influenced by dissimilarities between the patient and control groups.

Conclusions

The present preliminary study is the first to suggest an association between the 894G/T eNOS gene polymorphism and CSFP in the Iranian population. However, our results demonstrated no association between CSFP and the 315C/T IL-1β gene variant. Further, the allelic distribution and the presence of the variant allele of the 894G/T eNOS gene polymorphism were statistically associated with CSFP.

Availability of data and materials

All the oligos and the information regarding the study are provided in the paper. The accession numbers of the nucleotide transitions are 894G/T (rs1799983) for the eNOS change and 315C/T (rs1143634) for the IL-1β change (https://www.ncbi.nlm.nih.gov/search/all/?term=dbsnp). HGMD (http://www.hgmd.cf.ac.uk/ac/index.php), NCBI (www.ncbi.nlm.nih.gov/clinvar), UCSC (https://genome.ucsc.edu), and VarSome (https://varsome.com/) databases were utilized to investigate the selected SNPs and the pathogenesis of the selected nucleotide variations. The accession numbers and all the repositories used for the study are both mentioned in the article and declarations part as well.

References

  1. Beltrame JF, Limaye SB, Wuttke RD, Horowitz JD. Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon. Am Heart J. 2003;146(1):84–90.

    Article  PubMed  Google Scholar 

  2. Cutri N, Zeitz C, Kucia AM, Beltrame JF. ST/T wave changes during acute coronary syndrome presentation in patients with the coronary slow flow phenomenon. Int J Cardiol. 2011;146(3):457–8.

    Article  PubMed  Google Scholar 

  3. Mangieri E, Macchiarelli G, Ciavolella M, Barillà F, Avella A, Martinotti A, Dell’Italia LJ, Scibilia G, Motta P, Campa PP. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn. 1996;37(4):375–81.

    Article  CAS  PubMed  Google Scholar 

  4. Wang X, Nie S-P. The coronary slow flow phenomenon: characteristics, mechanisms and implications. Cardiovasc Diagn Ther. 2011;1(1):37.

    PubMed  PubMed Central  Google Scholar 

  5. Barutcu I, Sezgin AT, Sezgin N, Gullu H, Esen AM, Topal E, Ozdemir R. Elevated plasma homocysteine level in slow coronary flow. Int J Cardiol. 2005;101(1):143–5.

    Article  PubMed  Google Scholar 

  6. Mutluer FO, Ural D, Güngör B, Bolca O, Aksu T. Interleukin-1 gene cluster polymorphisms associated with coronary slow flow phenomenon. Cardiol. 2015;115(7 Suppl):8B-21B.

    Google Scholar 

  7. Mutluer FO, Ural D, Güngör B, Bolca O, Aksu T. Association of Interleukin-1 Gene cluster polymorphisms with coronary slow flow phenomenon. Anatol J Cardiol 2018; 19(1):0.

  8. Diah M, Lelo A, Muhktar Z, Lindarto D. Analysis of two single-nucleotide polymorphisms (rs2241766 and rs1501299) of the adiponectin gene in patients with coronary artery disease and coronary slow flow. Med Glas (Zenica). 2020;17(2):341–5.

    Google Scholar 

  9. Sezgin N, Tekin A, Atac FB, Verdi H, Sezgin AT. Endothelial nitric oxide synthase gene polymorphisms in patients with slow coronary flow. Interv Med Appl Sci. 2017;9(3):117–22.

    PubMed  PubMed Central  Google Scholar 

  10. Marletta MA. Nitric oxide: biosynthesis and biological significance. Trends Biochem Sci. 1989;14(12):488–92.

    Article  CAS  PubMed  Google Scholar 

  11. Golser R, Gorren AC, Mayer B, Schmidt K. Functional characterization of Glu298Asp mutant human endothelial nitric oxide synthase purified from a yeast expression system. Nitric Oxide. 2003;8(1):7–14.

    Article  CAS  PubMed  Google Scholar 

  12. Kugiyama K, Ohgushi M, Motoyama T, Sugiyama S, Ogawa H, Yoshimura M, Inobe Y, Hirashima O, Kawano H, Soejima H. Nitric oxide-mediated flow-dependent dilation is impaired in coronary arteries in patients with coronary spastic angina. J Am Coll Cardiol. 1997;30(4):920–6.

    Article  CAS  PubMed  Google Scholar 

  13. Cai H, Wilcken DE, Wang XL. The Glu-298→ Asp (894G→ T) mutation at exon 7 of the endothelial nitric oxide synthase gene and coronary artery disease. J Mol Med. 1999;77(6):511–4.

    Article  CAS  PubMed  Google Scholar 

  14. Casas JP, Bautista LE, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. Circulation. 2004;109(11):1359–65.

    Article  CAS  PubMed  Google Scholar 

  15. Hingorani AD, Liang CF, Fatibene J, Lyon A, Monteith S, Parsons A, Haydock S, Hopper RV, Stephens NG, O’Shaughnessy KM. A common variant of the endothelial nitric oxide synthase (Glu298→ Asp) is a major risk factor for coronary artery disease in the UK. Circulation. 1999;100(14):1515–20.

    Article  CAS  PubMed  Google Scholar 

  16. Berger K, Stögbauer F, Stoll M, Wellmann J, Huge A, Cheng S, Kessler C, John U, Assmann G, Ringelstein EB. The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case–control studies. Hum Genet. 2007;121(2):169–78.

    Article  CAS  PubMed  Google Scholar 

  17. Bertrand ME, LaBlanche JM, Tilmant PY, Thieuleux FA, Delforge MR, Carre AG, Asseman P, Berzin B, Libersa C, Laurent JM. Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography. Circulation. 1982;65(7):1299–306.

    Article  CAS  PubMed  Google Scholar 

  18. Tasolar H, Akturk E, Eyyupkoca F, Cansel M, Yagmur J, Ozyalin F, Pekdemir H, Karakus Y, Altun B. Endothelial nitric oxide synthase levels and their response to exercise in patients with slow coronary flow. Cardiovasc J Afr. 2013;24(9):355–9.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Yucel H, Ozaydin M, Dogan A, Erdogan D, Turker Y, Ceyhan BM, Sutcu R. Plasma concentrations of asymmetric dimethylarginine, nitric oxide and homocysteine in patients with slow coronary flow. Scand J Clin Lab Invest. 2012;72(6):495–500.

    Article  CAS  PubMed  Google Scholar 

  20. Sezgin N, Barutcu I, Sezgin AT, Gullu H, Turkmen M, Esen AM, Karakaya O. Plasma nitric oxide level and its role in slow coronary flow phenomenon. Int Heart J. 2005;46(3):373–82.

    Article  CAS  PubMed  Google Scholar 

  21. Moyer CF, Sajuthi D, Tulli H, Williams J. Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. Am J Pathol. 1991;138(4):951.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Ekmekci A, Güngör B, Özcan KS, Abaci N, Ilhan E, Ekmekci SS, Kemaloglu T, Osmonov D, Üstek D, Eren M. Evaluation of coronary microvascular function and nitric oxide synthase intron 4a/b polymorphism in patients with coronary slow flow. Coron Artery Dis. 2013;24(6):461–7.

    Article  PubMed  Google Scholar 

  23. Gazi E, Temiz A, Altun B, Barutcu A, Silan F, Colkesen Y, Ozdemir O. Endothelial function and germ-line ACE I/D, eNOS and PAI-1 gene profiles in patients with coronary slow flow in the Canakkale population: multiple thrombophilic gene profiles in coronary slow flow: cardiovascular topic. Cardiovasc J Afr. 2014;25(1):9–14.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Gupta MD, Akkarappatty C, Girish MP, Kumar R, Rain M, Tyagi S, Pasha MAQ. Association between the Glu298Asp and 4b/4a polymorphisms of endothelial nitric oxide synthase and coronary slow flow in the North Indian population. Coron Artery Dis. 2014;25(3):192–7.

    Article  PubMed  Google Scholar 

  25. Tsimikas S, Duff GW, Berger PB, Rogus J, Huttner K, Clopton P, Brilakis E, Kornman KS, Witztum JL. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J Am Coll Cardiol. 2014;63(17):1724–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93(5):879–88.

    Article  CAS  PubMed  Google Scholar 

  27. Lozano-Calderón S, Anthony S, Ring D. The quality and strength of evidence for etiology: example of carpal tunnel syndrome. J Hand Surg. 2008;33(4):525–38.

    Article  Google Scholar 

  28. Wiberg A, Ng M, Schmid AB, Smillie RW, Baskozos G, Holmes MV, Künnapuu K, Mägi R, Bennett DL, Furniss D. A genome-wide association analysis identifies 16 novel susceptibility loci for carpal tunnel syndrome. Nat Commun. 2019;10(1):1–12.

    Article  CAS  Google Scholar 

  29. The UCSC Genome Browser, http://genome.ucsc.edu/, accessed may 2019.

  30. Werner RA, Andary M. Carpal tunnel syndrome: pathophysiology and clinical neurophysiology. Clin Neurophysiol. 2002;113(9):1373–81.

    Article  PubMed  Google Scholar 

  31. Camara-Lemarroy CR, Gonzalez-Moreno EI, Guzman-de la Garza FJ, Fernandez-Garza NE. Arachidonic acid derivatives and their role in peripheral nerve degeneration and regeneration. Sci World J 2012; 2012.

  32. Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries–a new angiographic finding. Am Heart J. 1972;84(1):66–71.

    Article  CAS  PubMed  Google Scholar 

  33. Camsarl A, Pekdemir H, Cicek D, Polat G, Akkus MN, Döven O, Cin VG, Katlrclbasl T, Parmakslz T. Endothelin-1 and nitric oxide concentrations and their response to exercise in patients with slow coronary flow. Circ J. 2003;67(12):1022–8.

    Article  PubMed  Google Scholar 

  34. Zengin H, Erbay AR, Okuyucu A, Alaçam H, Yüksel S, Meriç M, Soylu K, Gedikli Ö, Murat N, Gülel O, et al. The relationship between coronary slow flow phenomenon and urotensin-II: a prospective and controlled study. Anatol J Cardiol. 2015;15(6):475–9.

    Article  CAS  PubMed  Google Scholar 

  35. Aksan G, Soylu K, Aksoy O, Özdemir M, Yanik A, Yuksel S, Gedikli Ö, Gulel O, Sahin M. The relationship between neutrophil gelatinase-associated Lipocalin levels and the slow coronary flow phenomenon. Coron Artery Dis. 2014;25(6):505–9.

    Article  PubMed  Google Scholar 

  36. Soylu K, Gulel O, Yucel H, Yuksel S, Aksan G, Soylu A, Demircan S, Yılmaz O, Sahin M. The effect of blood cell count on coronary flow in patients with coronary slow flow phenomenon. Pak J Med Sci. 2014;30(5):936–41.

    PubMed  PubMed Central  Google Scholar 

  37. Nejatizadeh A, Kumar R, Stobdan T, Goyal A, Sikdar S, Gupta M, Javed S, Pasha MQ. Endothelial nitric oxide synthase gene haplotypes and circulating nitric oxide levels significantly associate with risk of essential hypertension. Free Radical Biol Med. 2008;44(11):1912–8.

    Article  CAS  Google Scholar 

  38. Periaswamy R, Gurusamy U, Shewade DG, Cherian A, Swaminathan RP, Dutta TK, Jayaraman B, Chandrasekaran A. Gender specific association of endothelial nitric oxide synthase gene (Glu298Asp) polymorphism with essential hypertension in a south Indian population. Clin Chim Acta. 2008;395(1–2):134–6.

    Article  CAS  PubMed  Google Scholar 

  39. Tambe A, Demany M, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries—a new angiographic finding. Am Heart J. 1972;84(1):66–71.

    Article  CAS  PubMed  Google Scholar 

  40. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Investig. 1995;95(4):1747–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Rossi GP, Seccia TM, Nussdorfer GG. Reciprocal regulation of endothelin-1 and nitric oxide: relevance in the physiology and pathology of the cardiovascular system. Int Rev Cytol. 2001;209:241–72.

    Article  CAS  PubMed  Google Scholar 

  42. Francis SE, Camp NJ, Burton AJ, Dewberry RM, Gunn J, Stephens-Lloyd A, Cumberland DC, Gershlick A, Crossman DC. Interleukin 1 receptor antagonist gene polymorphism and restenosis after coronary angioplasty. Heart. 2001;86(3):336–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Manzoli A, Andreotti F, Varlotta C, Mollichelli N, Verde M, van de Greef W, Sperti G, Maseri A. Allelic polymorphism of the interleukin-1 receptor antagonist gene in patients with acute or stable presentation of ischemic heart disease. Cardiologia. 1999;44(9):825–30.

    CAS  PubMed  Google Scholar 

  44. Worrall BB, Azhar S, Nyquist PA, Ackerman RH, Hamm TL, DeGraba TJ. Interleukin-1 receptor antagonist gene polymorphisms in carotid atherosclerosis. Stroke. 2003;34(3):790–3.

    Article  CAS  PubMed  Google Scholar 

  45. Shi GL, Cai XX, Su YM, Chen C, Deng XT, Pan HY, Fan MK, Zhu JH, Pan M. Interleukin-10 promotor -592A/C polymorphism is associated with slow coronary flow in Han Chinese. Int J Clin Exp Pathol. 2015;8(4):4091–8.

    PubMed  PubMed Central  Google Scholar 

  46. Pan Q, Hui D, Hu C. A Variant of IL1B Is Associated with the Risk and Blood Lipid Levels of Myocardial Infarction in Eastern Chinese Individuals. Immunol Investig 2021; 1–8.

  47. Fang Y, Xie H, Lin Z. Association between IL-1β+ 3954C/T polymorphism and myocardial infarction risk: a meta-analysis. Medicine 2018; 97(30).

  48. Mutluer FO, Ural D, Güngör B, Bolca O, Aksu T. Association of Interleukin-1 Gene cluster polymorphisms with coronary slow flow phenomenon. Anatol J Cardiol. 2018;19(1):34–41.

    CAS  PubMed  Google Scholar 

  49. Pan Q, Hui D, Hu C. A Variant of IL1B is associated with the risk and blood lipid levels of myocardial infarction in eastern Chinese individuals. Immunol Invest 2021; 1–8.

  50. Nurkalem Z, Tangurek B, Zencirci E, Alper AT, Aksu H, Erer B, Gorgulu S, Ciloglu F, Eren M. Endothelial nitric oxide synthase gene (T-786C) polymorphism in patients with slow coronary flow. Coron Artery Dis. 2008;19(2):85–8.

    Article  PubMed  Google Scholar 

  51. Bryda J, Watroba S. The proinflammatory role of lipoxygenases in rheumatoid arthritis. J Pre-Clin Clin Res 2018, 12(4).

  52. Phillis JW, Horrocks LA, Farooqui AA. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev. 2006;52(2):201–43.

    Article  CAS  PubMed  Google Scholar 

  53. Wang X, Mo X, Zhang H, Zhang Y, Shen Y. Identification of phosphorylation associated SNPs for blood pressure, coronary artery disease and stroke from genome-wide association studies. Curr Mol Med. 2019;19(10):731–8.

    Article  CAS  PubMed  Google Scholar 

  54. Armstrong NJ, Mather KA, Sargurupremraj M, Knol MJ, Malik R, Satizabal CL, Yanek LR, Wen W, Gudnason VG, Dueker ND. Common genetic variation indicates separate causes for periventricular and deep white matter hyperintensities. Stroke. 2020;51(7):2111–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Ben Ali M, Messaoudi S, Ezzine H, Mahjoub T. Contribution of eNOS variants to the genetic susceptibility of coronary artery disease in a Tunisian population. Genet Test Mol Biomark. 2015;19(4):203–8.

    Article  CAS  Google Scholar 

  56. Nawaz SK, Rani A, Yousaf M, Noreen A, Arshad M. Genetic etiology of coronary artery disease considering NOS 3 gene variant rs1799983. Vascular. 2015;23(3):270–6.

    Article  CAS  PubMed  Google Scholar 

  57. Caglayan AO, Kalay N, Saatci C, Yalcın A, Akalın H, Dundar M. Lack of association between the Glu298Asp polymorphism of endothelial nitric oxide synthase and slow coronary flow in the Turkish population. Can J Cardiol. 2009;25(3):e69–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Kiani R, Alilou S, Rafatnia S, Taslimi Y, Habibzadeh S, Gharibzadeh S, Rafati S, Firouzi A, Rahimi S, Zahedmehr A. Role of polymorphisms of the endothelial nitric oxide synthase gene in predicting slow-flow phenomenon after primary percutaneous coronary intervention. Turk Kardiyoloji Dernegi Arsivi. 2020;48(5):472–83.

    PubMed  Google Scholar 

  59. Heidari MM, Khatami M, Tahamtan Y. Molecular analysis of rs2070744 and rs1799983 polymorphisms of NOS3 gene in Iranian patients with multiple sclerosis. Basic Clin Neurosci. 2017;8(4):279.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Joshaghani HR, Salehi A, Samadian E, Gharaei R, Ahmadi AR. Association between NOS3 G894T, T-786C and 4a/4b Variants and coronary artery diseases in Iranian population. Iran J Public Health. 2018;47(12):1891.

    PubMed  PubMed Central  Google Scholar 

  61. Gulec S, Karabulut H, Ozdemir AO, Ozdol C, Turhan S, Altın T, Tutar E, Genc Y, Erol C. Glu298Asp polymorphism of the eNOS gene is associated with coronary collateral development. Atherosclerosis. 2008;198(2):354–9.

    Article  CAS  PubMed  Google Scholar 

  62. Naber CK, Baumgart D, Altmann C, Siffert W, Erbel R, Heusch G. eNOS 894T allele and coronary blood flow at rest and during adenosine-induced hyperemia. Am J Physiol Heart Circ Physiol. 2001;281(5):H1908–12.

    Article  CAS  PubMed  Google Scholar 

  63. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002;105(5):656–62.

    Article  PubMed  Google Scholar 

  64. Sianos G, Morel M-A, Kappetein AP, Morice M-C, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1(2):219–27.

    PubMed  Google Scholar 

  65. Zhao J, Yang Y, You S, Jing Z, Wu Y, Yang W, Chen J, Gao R, Chen Z. Effect of adenosine on endothelin-1 in the infarcted reflow and no-reflow myocardium of mini-swine. Zhongguo yi xue ke xue Yuan xue bao Acta Academiae Medicinae Sinicae. 2006;28(2):225–9.

    CAS  PubMed  Google Scholar 

  66. Nasr HB, Dimassi S. M’hadhbi R, Debbabi H, Kortas M, Tabka Z, Chahed K: Functional G894T (rs1799983) polymorphism and intron-4 VNTR variant of nitric oxide synthase (NOS3) gene are susceptibility biomarkers of obesity among Tunisians. Obes Res Clin Pract. 2016;10(4):465–75.

    Article  PubMed  Google Scholar 

  67. Arafa S, Abdelsalam S, El-Gilany A-H, Mosaad YM, Abdel-Ghaffar A. Endothelial nitric oxide synthase Glu 298 Asp (G894T) and Apolipoprotein E gene polymorphism as possible risk factors for coronary heart disease among Egyptians. Egypt Heart J. 2018;70(4):393–401.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank the patients and the healthy individuals for their kind participation in the study. We are also grateful to Maryam Zarin Sadaf for her technical assistance.

Funding

This work was supported by a research grant to Dr Sadeghipour and Dr Malakootian from the Research Deputyship of Rajaie Cardiovascular Medical and Research Center (9960).

Author information

Authors and Affiliations

  1. Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

    Yeganeh Karimi, Fatemeh Sehati, Ali Sarreshtedari, Mina Mirzad, Farzaneh Mehrvarz & Hooman Bakhshandeh

  2. Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Vali-Asr Ave, Niyayesh Blvd, Tehran, 1996911101, Iran

    Reza Kiani, Maryam Parham & Parham Sadeghipour

  3. Cardiogenetic Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Vali-Asr Ave, Niyayesh Blvd, Tehran, 1996911101, Iran

    Yasaman Khalili, Maryam Hosseini Moghadam, Mahshid Malakootian & Parham Sadeghipour

  4. Molecular Genetics Department, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran

    Elham Taheri Bajgan

Authors
  1. Yeganeh Karimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fatemeh Sehati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali Sarreshtedari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mina Mirzad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasaman Khalili
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Reza Kiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Elham Taheri Bajgan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maryam Hosseini Moghadam
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Farzaneh Mehrvarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hooman Bakhshandeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Maryam Parham
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Mahshid Malakootian
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Parham Sadeghipour
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YK: experiment design, data production, data interpretation, writing the first draft of the manuscript, and the final edit of the manuscript. FS: clinical evaluation of patients, and the final edit of the manuscript. AS: clinical evaluation of patients, and the final edit of the manuscript. MM: lab work, data production, and the final edit of the manuscript. YKh: WES analysis and the final edit of the manuscript. RK: clinical evaluation of patients, and the final edit of the manuscript. ETB: experiment design, data production, and the final edit of the manuscript. MHM: experiment design, data production, and the final edit of the manuscript. FM: clinical evaluation of patients, and the final edit of the manuscript. HB: data analysis,, and the final edit of the manuscript. MP: clinical evaluation of patients, and the final edit of the manuscript. MM: experiment design, data production, data interpretation, and the final edit of the manuscript. PS: clinical evaluation of patients, data production, data interpretation, and the final edit of the manuscript. All the authors contributed to the article and approved the submitted version. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Mahshid Malakootian or Parham Sadeghipour.

Ethics declarations

Ethical approval and consent to participate

The study protocol was approved by the Ethics Committee of Rajaie Cardiovascular Medical and Research Center (IR.RHC.REC.1399.075). The study was conducted in accordance with the Helsinki Declaration. All the individuals who joined the study signed written informed consent.

Consent for publication

Not applicable.

Competing interests

All the authors have read and approved the data presented in the manuscript and declare that there are no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1:

Multivariable regression analysis between the TIMI frame count for the LAD and clinical and genetic parameters in the patients.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karimi, Y., Sehati, F., Sarreshtedari, A. et al. Endothelial nitric oxide synthase Asp298Glu (894G/T) gene polymorphism as a possible risk factor for the coronary slow flow phenomenon among Iranians. BMC Cardiovasc Disord 22, 300 (2022). https://doi.org/10.1186/s12872-022-02736-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12872-022-02736-0

Keywords

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us